Johri Apurva Virmani, Johri Pranav, Hoyle Naomi, Pipia Levan, Nadareishvili Lia, Nizharadze Dea
Vitalis Phage Therapy, New Delhi, India.
Eliava Phage Therapy Center, Tbilisi, Georgia.
Front Pharmacol. 2021 Jun 10;12:692614. doi: 10.3389/fphar.2021.692614. eCollection 2021.
Chronic Bacterial Prostatitis (CBP) is an inflammatory condition caused by a persistent bacterial infection of the prostate gland and its surrounding areas in the male pelvic region. It is most common in men under 50 years of age. It is a long-lasting and debilitating condition that severely deteriorates the patient's quality of life. Anatomical limitations and antimicrobial resistance limit the effectiveness of antibiotic treatment of CBP. Bacteriophage therapy is proposed as a promising alternative treatment of CBP and related infections. Bacteriophage therapy is the use of lytic bacterial viruses to treat bacterial infections. Many cases of CBP are complicated by infections caused by both nosocomial and community acquired multidrug resistant bacteria. Frequently encountered strains include Vancomycin resistant , Extended Spectrum Beta Lactam resistant , other gram-positive organisms such as and , such as and , and , among others. We present a patient with the typical manifestations of CBP. The patient underwent multiple courses of antibiotic treatment without any long-term resolution of his symptoms. Testing of prostatic secretion and semen samples revealed pathogenic bacteria in each case, which collectively included members of the Staphylococcal species such as Methicillin resistant (MRSA) and , , and , among others. Bacteriophage preparations from the Eliava Institute were used to treat the patient after establishing phage sensitivity to the pathogenic bacteria. Significant improvements in symptoms and re-testing of samples after bacteriophage treatment indicated a reduction in the bacterial load and resolution of the infection. The patient saw significant improvement of symptoms, and positive dynamics in bacterial titers and ultrasound controls after phage therapy. The failure of antibiotic therapy and subsequent success of bacteriophage therapy in treating chronic bacterial prostatitis shows the effectiveness of bacteriophages in controlling chronic infections in areas of low vascularity and anatomical complexity. These cases also highlight the efficacy of phages in overcoming antibiotic-resistant infections as well as biofilm infections.
慢性细菌性前列腺炎(CBP)是一种由男性盆腔区域前列腺及其周围区域持续细菌感染引起的炎症性疾病。它在50岁以下男性中最为常见。这是一种持久且使人衰弱的疾病,会严重恶化患者的生活质量。解剖学限制和抗菌耐药性限制了CBP抗生素治疗的效果。噬菌体疗法被认为是CBP及相关感染的一种有前景的替代治疗方法。噬菌体疗法是利用裂解性细菌病毒来治疗细菌感染。许多CBP病例因医院获得性和社区获得性多重耐药细菌引起的感染而复杂化。常见菌株包括耐万古霉素、超广谱β-内酰胺耐药菌,以及其他革兰氏阳性菌,如 、 , 如 、 ,还有 等。我们介绍一位具有CBP典型表现的患者。该患者接受了多个疗程的抗生素治疗,但症状没有得到任何长期缓解。前列腺分泌物和精液样本检测在每种情况下都发现了病原菌,其中共同包括葡萄球菌属成员,如耐甲氧西林 (MRSA)和 、 、 等。在确定噬菌体对病原菌的敏感性后,使用来自埃利亚瓦研究所的噬菌体制剂治疗该患者。噬菌体治疗后症状有显著改善,样本重新检测表明细菌载量减少且感染得到解决。患者在噬菌体治疗后症状有显著改善,细菌滴度和超声检查有积极变化。抗生素治疗失败,随后噬菌体治疗成功治疗慢性细菌性前列腺炎,这表明噬菌体在控制低血管性和解剖复杂性区域的慢性感染方面是有效的。这些病例还突出了噬菌体在克服抗生素耐药感染以及生物膜感染方面的功效。